

# A Study to Assess Disease Activity in Adult Participants With Axial Spondyloarthritis Who Receive Upadacitinib in a Real-world Setting

NCT05094128

---

**Status** RECRUITING  
**Sponsor** AbbVie  
**Enrollment** 352 participants

## Key Eligibility Criteria

---

### Inclusion (3)

- Clinical diagnosis of axSpA upon physician's judgement.
- Physician decision on participant treatment with upadacitinib must have been reached prior to and independently of recruitment in the study.
- Upadacitinib prescribed in accordance with the local label.

### Exclusion (4)

- Prior exposure to any Janus kinase (JAK) inhibitor (including but not limited to upadacitinib, tofacitinib, baricitinib, and filgotinib).
- Participants with primary fibromyalgia (upon physician's judgement)
- Participation in a clinical trial of an investigational drug, concurrently or within the last 30 days or five half-lives of the drug (whichever is longer) prior to the first dose of study drug or is currently enrolled in another clinical study.
- Participants who cannot be treated with upadacitinib according to the applicable local label.

## Locations (72 total)

---

ACURA Rheumazentrum Baden-Bade /ID# 249751, Baden-Baden, Baden-Wurttemberg, Germany  
Heilig, Heidelberg, DE /ID# 240492, Heidelberg, Baden-Wurttemberg, Germany  
Rheumatologische Schwerpunktpraxis /ID# 245392, Stuttgart, Baden-Wurttemberg, Germany  
... and 69 more locations